{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/importance-early-integration-liquid-biopsy-enhance-oncology-research#webpage",
"url": "https://www.fortrea.com/insights/importance-early-integration-liquid-biopsy-enhance-oncology-research",
"name": "The importance of early integration of liquid biopsy to enhance oncology research",
"description": "Explore this Fortrea white paper on liquid biopsy in oncology research and discover how early integration of liquid biopsy technologies is advancing precision oncology, biomarker discovery, and oncology clinical trial innovation. The white paper examines how circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other non-invasive oncology biomarkers are helping improve patient selection, enable real-time tumor monitoring, and support more adaptive oncology trial designs. Learn how liquid biopsy strategies enhance precision oncology research through biomarker-driven decision-making, treatment response tracking, minimal residual disease monitoring, and longitudinal cancer assessment while helping sponsors optimize oncology clinical development and accelerate personalized cancer therapy innovation."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "The importance of early integration of liquid biopsy to enhance oncology research",
"item": "https://www.fortrea.com/insights/importance-early-integration-liquid-biopsy-enhance-oncology-research"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/importance-early-integration-liquid-biopsy-enhance-oncology-research#whitepaper",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/importance-early-integration-liquid-biopsy-enhance-oncology-research#webpage"
},
"headline": "Liquid Biopsy in Precision Oncology Research & Clinical Trial Innovation | Fortrea White Paper",
"description": "Explore this Fortrea white paper on liquid biopsy in oncology research and discover how early integration of liquid biopsy technologies is advancing precision oncology, biomarker discovery, and oncology clinical trial innovation. The white paper examines how circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other non-invasive oncology biomarkers are helping improve patient selection, enable real-time tumor monitoring, and support more adaptive oncology trial designs. Learn how liquid biopsy strategies enhance precision oncology research through biomarker-driven decision-making, treatment response tracking, minimal residual disease monitoring, and longitudinal cancer assessment while helping sponsors optimize oncology clinical development and accelerate personalized cancer therapy innovation.",
"genre": "White Paper",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2025-03/liquid-biopsy-to-enhance-oncology-research.jpg"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2025-03-17",
"dateModified": "2025-03-17",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2025-03/liquid-biopsy-to-enhance-oncology-research_0.pdf",
"encodingFormat": "application/pdf"
}
}
]
}